Transurethral holmium laser enucleation of the prostate combined with Jisheng Shenqi Decoction for benign prostatic hyperplasia.
- Author:
Wei WANG
1
;
Jian-Jun YANG
1
;
Guan-Tian YANG
1
;
Xiang ZHOU
1
;
Yong-Feng DING
1
;
Xiang-Nong HU
1
;
Wei ZHU
1
;
Zheng-Ping YANG
1
Author Information
1. Department of Urology, Jiangsu Provincial Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine / Jiangsu Branch of Chinese Academy of Traditional Chinese Medicine / Jiangsu Research Institute of Traditional Chinese Medicine, Nanjing, Jiangsu 210028, China.
- Publication Type:Journal Article
- Keywords:
benign prostatic hyperplasia;
maximum urinary flow rate;
postvoid residual urine;
prostate volume;
reproductive hormone;
transurethral holmium laser enucleation of the prostate;
Jisheng Shenqi Decoction
- From:National Journal of Andrology
2019;25(5):351-355
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To assess the clinical effects of transurethral holmium laser enucleation of the prostate (HoLEP) combined with Jisheng Shenqi Decoction (HoLEP + JSSD) on BPH.
METHODS:This study included 110 BPH patients treated in our hospital from August 2017 to April 2018, who were randomly assigned to receive HoLEP (n = 55) or HoLEP + JSSD (n = 55). We compared the pre- and post-operative IPSS, quality of life (QOL) score, prostate volume, postvoid residual urine volume (PVR), maximum urinary flow rate (Qmax), average urinary flow rate (Qavg) and levels of serum T, E2 and T/E2 as well as postoperative complications between the two groups of patients.
RESULTS:After treatment, both IPSS and QOL score were significantly lower in the HoLEP + JSSD than in the HoLEP group (P < 0.05), and so were the prostate volume and PVR (P < 0.05). The Qmax, Qavg and serum T level were significantly higher (P < 0.05) while T/E2 markedly lower in the former than in the latter group (P < 0.05). There were no statistically significant differences between the HoLEP + JSSD and HoLEP groups in the E2 level (P > 0.05) or the total incidence rate of complications postoperatively (21.82% vs 29.09%, P > 0.05).
CONCLUSIONS:HoLEP + JSSD can significantly alleviate the lower urinary tract symptoms as well as improve the QOL and bladder and urinary tract functions of BPH patients.
